Creso Pharma Ltd. (1X8.SG)
| Previous Close | 0.0238 |
| Open | 0.0237 |
| Bid | 0.0239 x 0 |
| Ask | 0.0254 x 0 |
| Day's Range | 0.0237 - 0.0237 |
| 52 Week Range | 0.0237 - 0.1000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
Halucenex to receive recently harvested first batch of psilocybe cubensis Optimi Head of Cultivation, Todd Henderson Optimi Head of Cultivation, Todd Henderson, navigates Optimi's new fruiting chamber. Psilocybin Cubensis Optimi psilocybin cubensis (liquid culture). VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom f
- CNW Group
Sierra Sage Herbs Acquired By Creso Pharma
Sierra Sage Herbs, maker of the best-selling Green Goo, Southern Butter and Good Goo natural products brands, announced today its acquisition by Australia's Creso Pharma Limited (ASX: CPH, OTC: COPHF, FRA: 1X8). The deal extends Creso's global footprint to the US market while adding an additional range of natural health products to its existing lines of cannabis and hemp-based pharmaceuticals. Sierra Sage, which counts 90,000 points of distribution across the US including Whole Foods, Walmart, A
- Business Wire
SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient
WATERTOWN, Mass., December 09, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Of the five patients in this cohort eva
